Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 76 results
Author
Title
Type
[
Year
]
Filters:
Keyword
is
Humans
[Clear All Filters]
2018
Dogan B
,
Belcher-Timme HFacey
,
Dogan EI
,
Jiang Z-D
,
Dupont HL
,
Snyder N
,
Yang S
,
Chandler B
,
Scherl EJ
,
Simpson KW
. 2018.
Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.
.
FEMS Microbiol Lett. 365(22)
Kumar A
,
Kim M
,
Lukin DJ
. 2018.
Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors.
.
Indian J Gastroenterol. 37(3):235-242.
Cohen-Mekelburg S
,
Rosenblatt R
,
Gold S
,
Burakoff R
,
Waljee AK
,
Saini S
,
Schackman BR
,
Scherl E
,
Crawford C
. 2018.
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.
.
J Crohns Colitis. 12(9):1030-1035.
Castellanos JG
,
Woo V
,
Viladomiu M
,
Putzel G
,
Lima S
,
Diehl GE
,
Marderstein AR
,
Gandara J
,
Perez AR
,
Withers DR
et al.
. 2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
.
Immunity. 49(6):1077-1089.e5.
Ghosh G
,
Jacob V
,
Wan D
. 2018.
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.
.
Clin Gastroenterol Hepatol. 16(4):e41-e42.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Dogan B
,
Fu J
,
Zhang S
,
Scherl EJ
,
Simpson KW
. 2018.
Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.
.
J Antibiot (Tokyo). 71(5):485-494.
Cohen-Mekelburg S
,
Tafesh Z
,
Coburn E
,
Weg R
,
Malik N
,
Webb C
,
Hammad H
,
Scherl E
,
Bosworth BP
. 2018.
Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
.
Dig Dis Sci. 63(9):2439-2444.
Gold SL
,
Magro C
,
Scherl E
. 2018.
A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.
.
Gastroenterology. 155(4):981-982.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
2017
Battat R
,
Kopylov U
,
Bessissow T
,
Bitton A
,
Cohen A
,
Jain A
,
Martel M
,
Seidman E
,
Afif W
. 2017.
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Viladomiu M
,
Kivolowitz C
,
Abdulhamid A
,
Dogan B
,
Victorio D
,
Castellanos JG
,
Woo V
,
Teng F
,
Tran NL
,
Sczesnak A
et al.
. 2017.
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.
.
Sci Transl Med. 9(376)
J Blander M
,
Longman RS
,
Iliev ID
,
Sonnenberg GF
,
Artis D
. 2017.
Regulation of inflammation by microbiota interactions with the host.
.
Nat Immunol. 18(8):851-860.
Jacob V
,
Crawford C
,
Cohen-Mekelburg S
,
Viladomiu M
,
Putzel GG
,
Schneider Y
,
Chabouni F
,
OʼNeil S
,
Bosworth B
,
Woo V
et al.
. 2017.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.
.
Inflamm Bowel Dis. 23(6):903-911.
Battat R
,
Kopylov U
,
Byer J
,
Sewitch MJ
,
Rahme E
,
Nedjar H
,
Zelikovic E
,
Dionne S
,
Bessissow T
,
Afif W
et al.
. 2017.
Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.
.
Eur J Gastroenterol Hepatol. 29(12):1361-1367.
2015
DeFilippis EM
,
Barfield E
,
Leifer D
,
Steinlauf A
,
Bosworth BP
,
Scherl EJ
,
Sockolow R
. 2015.
Cerebral venous thrombosis in inflammatory bowel disease.
.
J Dig Dis. 16(2):104-8.
Chen HJoyce
,
Sun J
,
Huang Z
,
Hou H
,
Arcilla M
,
Rakhilin N
,
Joe DJ
,
Choi J
,
Gadamsetty P
,
Milsom J
et al.
. 2015.
Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.
.
Nat Biotechnol. 33(6):656-60.
Dassopoulos T
,
Cohen RD
,
Scherl EJ
,
Schwartz RM
,
Kosinski L
,
Regueiro MD
. 2015.
Ulcerative Colitis Care Pathway.
.
Gastroenterology. 149(1):238-45.
2014
Longman RS
,
Diehl GE
,
Victorio DA
,
Huh JR
,
Galan C
,
Miraldi ER
,
Swaminath A
,
Bonneau R
,
Scherl EJ
,
Littman DR
. 2014.
CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.
.
J Exp Med. 211(8):1571-83.
Zhang N
,
Yantiss RK
,
Nam H-S
,
Chin Y
,
Zhou XKathy
,
Scherl EJ
,
Bosworth BP
,
Subbaramaiah K
,
Dannenberg AJ
,
Benezra R
. 2014.
ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.
.
Stem Cell Reports. 3(5):716-24.
Dogan B
,
Suzuki H
,
Herlekar D
,
R Sartor B
,
Campbell BJ
,
Roberts CL
,
Stewart K
,
Scherl EJ
,
Araz Y
,
Bitar PP
et al.
. 2014.
Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.
.
Inflamm Bowel Dis. 20(11):1919-32.
Battat R
,
Kopylov U
,
Szilagyi A
,
Saxena A
,
Rosenblatt DS
,
Warner M
,
Bessissow T
,
Seidman E
,
Bitton A
. 2014.
Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.
.
Inflamm Bowel Dis. 20(6):1120-8.
2013
Dogan B
,
Scherl E
,
Bosworth B
,
Yantiss R
,
Altier C
,
McDonough PL
,
Jiang Z-D
,
Dupont HL
,
Garneau P
,
Harel J
et al.
. 2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.
.
Inflamm Bowel Dis. 19(1):141-50.
Kothary V
,
Scherl EJ
,
Bosworth B
,
Jiang Z-D
,
Dupont HL
,
Harel J
,
Simpson KW
,
Dogan B
. 2013.
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
.
Antimicrob Agents Chemother. 57(2):811-7.
Montrose DC
,
Scherl EJ
,
Bosworth BP
,
Zhou XKathy
,
Jung B
,
Dannenberg AJ
,
Hla T
. 2013.
S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.
.
J Lipid Res. 54(3):843-51.
« first
‹ previous
1
2
(current)
3
4
next ›
last »